Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
13.84
-2.71 (-16.37%)
Oct 13, 2026, 3:49 PM EDT - Market open
Syndax Pharmaceuticals Revenue
Syndax Pharmaceuticals had revenue of $72.79M in the quarter ending June 30, 2026, with 91.76% growth. This brings the company's revenue in the last twelve months to $252.25M, up 222.65% year-over-year. In the year 2025, Syndax Pharmaceuticals had annual revenue of $172.35M with 627.84% growth. That makes Syndax Pharmaceuticals the 15,724th largest company in the world by revenue and 2,735th in the United States.
Revenue (ttm)
$252.25M
Revenue Growth
+222.65%
P/S Ratio
4.82
Revenue / Employee
$846,480
Employees
298
Market Cap
1.24B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 172.35M | 148.67M | 627.84% |
| Dec 31, 2024 | 23.68M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 139.71M | 138.19M | 9,109.56% |
| Dec 31, 2020 | 1.52M | - | - |
| Dec 31, 2019 | 1.52M | - | - |
| Dec 31, 2018 | 1.52M | -591.00K | -28.04% |
| Dec 31, 2017 | 2.11M | 888.00K | 72.79% |
| Dec 31, 2016 | 1.22M | 593.00K | 94.58% |
| Dec 31, 2015 | 627.00K | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Ultragenyx Pharmaceutical | 717.00M |
| Innoviva | 440.00M |
| Immunocore Holdings | 430.78M |
| Maze Therapeutics | 20.00M |
| uniQure | 18.67M |
| Taysha Gene Therapies | 5.49M |
SNDX News
- 6 hours ago - Syndax valuation unchanged after trial miss, says H.C. Wainwright - TheFly
- 6 hours ago - Syndax selloff brings attractive entry point, says Citi - TheFly
- 9 hours ago - Syndax price target lowered to $23 from $26 at BofA - TheFly
- 23 hours ago - Syndax says Phase 2 idiopathic pulmonary fibrosis study misses endpoint - TheFly
- 23 hours ago - Syndax says idiopathic pulmonary fibrosis study did not meet endpoint - TheFly
- 23 hours ago - Syndax to end development of axatilimab in idiopathic pulmonary fibrosis - TheFly
- 23 hours ago - Syndax sinks 15% to $14 after idiopathic pulmonary fibrosis miss - TheFly
- 23 hours ago - Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis - GlobeNewsWire